<DOC>
	<DOCNO>NCT01597908</DOCNO>
	<brief_summary>This two-arm , open-label , randomise , Phase III study compare dabrafenib ( GSK2118436 ) trametinib ( GSK1120212 ) combination therapy vemurafenib . Subjects histologically confirm cutaneous melanoma either stage IIIc ( unresectable ) stage IV , BRAF V600E/K mutation positive screen eligibility . Subjects prior systemic anti-cancer treatment advance metastatic set eligible although prior systemic treatment adjuvant setting allow . Approximately 694 subject randomise 1:1 ( combination therapy : vemurafenib ) . The primary endpoint overall survival ( OS ) subject receive combination therapy compare receive vemurafenib .</brief_summary>
	<brief_title>Dabrafenib Plus Trametinib v Vemurafenib Alone Unresectable Metastatic BRAF V600E/K Cutaneous Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>&gt; = 18 year age Stage IIIc Stage IV BRAF V600E/K cutaneous melanoma Measurable disease accord RECIST 1.1 Women childbearing potential negative serum pregnancy test prior randomisation Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate baseline organ function Any prior use BRAF MEK inhibitor Prior systemic anticancer treatment advance metastatic setting ; prior systemic treatment adjuvant setting allow History another malignancy ( except subject disease free 3 year history completely resect nonmelanoma skin cancer ) Known HIV , HBV , HCV infection ( except chronic clear HBV HCV infection allow ) Brain metastasis ( except know lesion previously treat surgery stereotactic radiosurgery lesion , still present , confirm stable &gt; = 12 week prior randomisation longer present confirm evidence disease &gt; = 12 week , asymptomatic corticosteroid requirement &gt; = 4 week prior randomisation , enzyme induce anticonvulsant &gt; = 4 week prior randomisation History evidence cardiovascular risk ( LVEF &lt; LLN ; QTcB &gt; = 480 msec ; blood pressure systolic &gt; =140 mmHg diastolic &gt; = 90 mmHg control antihypertensive therapy ) History current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BRAF inhibitor</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>MEK inhibitor</keyword>
</DOC>